

# CHO Media Portfolio

## Introduction

Business Use Only



## Current customer challenges



Tedious screening  
process for identifying  
high-performance  
media



Rigorous  
characterization for  
optimizing process  
parameters



Costly scalability  
studies and complex  
regulatory  
requirements

# Considerations for production of a recombinant therapeutic

Choice of medium can have many effects

## High protein expression levels


Cell lines should reproducibly express high levels of recombinant protein and maintain expression over time

\*Ease-of-manufacturing and cost consideration

## Quality attributes

Quality attributes that influence the safety and efficacy of the therapeutic protein must fall within defined ranges

\*Regulatory requirement for safety and efficacy



## Cell health

Optimal doubling times are ideal for bioproduction approaches requiring fast scale-up to large bioreactors

Resistance to apoptosis

\*Ease-of-manufacturing and cost consideration

## Clonality

A production cell line must be derived from a single-cell (aka: clonal) to minimize variability and the impact of process changes on product quality

\*Regulatory requirement for safety and efficacy

# Benefits of Lonza CHO Media portfolio offering

## Streamline



**Accelerate** your media screening and optimization using our advanced CHO media portfolio

## Achieve



**Generate** high cell yields with the optimal quality through our optimized media, renowned for their superior performance and scalability

## Secure




**Ensure** your success with our globally harmonized, regulatory-compliant media manufacturing and distribution network

# Lonza CHO Media portfolio | breadth

## Broad portfolio to cater your needs

### ProCHO® 5



- **First-generation medium**, non-chemically-defined, non-animal origin (NAO), serum-free
- **Focus:** CHO DG44, K1, DXB11
- Simple formulation to support adaptation and growth in suspension culture

### PowerCHO® 2



- Chemically-defined, non-animal origin (NAO), Serum-free
- **Focus:** CHO DG44, K1, DXB11
- Demonstrates consistent scalability across a range of scales.

### TheraPRO®



- **Newly launched**, Chemically-defined, non-animal origin (NAO), serum-free
- **Focus:** CHO-GS and CHO-K1
- Demonstrates consistent scalability across a range of scales

The Lonza ProCHO5 Media System, the first-generation CHO media, offers a hydrolysate-containing, cost-effective solution ideal for biosimilar manufacturing, combining affordability, robustness, and proven performance for scalable production from lab to large-scale

- First-generation media, non-chemically-defined, non-animal origin, serum-free
- Achieves high titer, consistent product quality, and improved scalability in various CHO cell lines
- Simple formulation to support adaptation and growth in suspension culture



The Lonza PowerCHO2 Media System, designed for the CHO-DG44 cell line, delivers a chemically-defined, high-performance solution that ensures consistent, high-quality recombinant protein production throughout all stages of biopharmaceutical development and manufacturing

- Chemically-defined, non-animal origin, serum-free
- Achieves high cell density and protein titer in various CHO DG44 cell lines in suspension
- Demonstrates scalability and consistency across various scales.



The Lonza TheraPRO® CHO Media System, with its advanced, chemically-defined, high-quality formulation for CHO-GS and CHO-K1 cell lines, simplifies preparation, enhances productivity, and scales seamlessly from research to commercial production

- Chemically-defined, Non-animal origin, serum-free
- Achieves high titers and product quality in CHO-GS and CHO-K1 cell lines
- Demonstrates scalability and consistency across various scales




# Lonza CHO Media portfolio

Solutions for protein production

**CHO GS, CHO K1**


**CHO DG44**



# Lonza's comprehensive solutions for therapeutic innovation

## Protein production made simple


### Cell line development



### Media and process optimization



### Commercial production



End-to-end Lonza product offerings



Easy-to-use, high performing technologies, with expert support



Offers liquid and powder production capabilities



Extensive Know-how in Development & Manufacturing of a Wide Range of Therapeutic Proteins



All manufacturing facilities adhere to ISO 9001, ISO 13485, 21 CFR 820 compliance

# Thank You!

We look forward to working with you soon.

> Visit us at [bioscience.lonza.com](https://bioscience.lonza.com)

